Application of polypeptides in preparation of medicament for treating or preventing rheumatoid arthritis

Abstract

The invention discloses application of polypeptides in preparation of medicament for treating or preventing rheumatoid arthritis, belongs to the field of medicament and particularly relates to polypeptides with integrin affinity and binding capacity. The polypeptides comprise a polypeptide I, a polypeptide II and a polypeptide III which can be used for preventing or treating rheumatoid arthritis; the polypeptide I has the following amino acid sequence: Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro, wherein the amino acid sequence comprises two pairs of disulfide bonds, and the disulfide bonds have the pairing mode of 1-4 and 2-3; the polypeptide II has the following amino acid sequence: Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp; and the polypeptide III has the following amino acid sequence: mPEG-SC20k-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp. The polypeptides can be used for treating the rheumatoid arthritis.

Description

[0001] This application is a divisional application with an application date of December 27, 2011, an application number of 201110443067.9, and an invention title of "Application of Polypeptides in the Preparation of Drugs for Treating or Preventing Rheumatoid Arthritis". technical field [0002] The invention relates to the field of medicine, in particular to a polypeptide for treating or preventing rheumatoid arthritis. Background technique [0003] Rheumatoid arthritis (RA) is the most common clinical inflammatory joint disease and one of the main disabling factors. It is about 0.5%-1.0% in the world, and the incidence of RA is about 0.4% in our country. RA can occur at any age, and the incidence rate increases with age. The high-incidence age of women is 45-55 years old, and gender is closely related to the incidence of RA, with a male-to-female ratio of about 1:3. RA is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovia...

AI Technical Summary

Problems solved by technology

2. Steroid hormones. Hormones are very good analgesic and anti-inflammatory drugs, but long-term use alone cannot improve the condition, but bring many side effects. Steroids can be used as a transitional second-line slow-acting drug before it takes effect, but the dosage should be limited. small, not too long

Although the previous patent ZL200510040378.5 discloses that the sequence has a therapeutic effect on melanoma, it does not disclose the therapeutic effect on other diseases

Images